Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial.

Background: In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin-piperaquine plus single, low-dose primaquine on Plasmodium falciparum incidence and prevalence in southeast Senegal.

A multiscale model for multivariate time series forecasting.

Transformer based models for time-series forecasting have shown promising performance and during the past few years different Transformer variants have been proposed in time-series forecasting domain. However, most of the existing methods, mainly represent the time-series from a single scale, making it challenging to capture various time granularities or ignore inter-series correlations between the series which might lead to inaccurate forecasts. In this paper, we address the above mentioned shortcomings and propose a Transformer based model which integrates multi-scale patch-wise temporal modeling and channel-wise representation.

Prevalence and factors associated with neonatal sepsis in Mali: a cross-sectional study.

Objective: This study aimed to assess the prevalence and risk factors for neonatal sepsis among neonates admitted to selected health facilities in the Bamako district and Koulikoro region in Mali.

Design: This is a prospective cross-sectional study. Data were analyses using bivariate and multivariate logistic regression.

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.